AngioDynamics ANGO Med Device — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about AngioDynamics's med device — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AngioDynamics's med device — gross profit?
- AngioDynamics (ANGO) reported med device — gross profit of $18.19M in Q4 2025.
- How has AngioDynamics's med device — gross profit changed year-over-year?
- AngioDynamics's med device — gross profit decreased by 5.6% year-over-year, from $19.27M to $18.19M.
- What is the long-term trend for AngioDynamics's med device — gross profit?
- Over 4 years (2021 to 2025), AngioDynamics's med device — gross profit has grown at a -9.3% compound annual growth rate (CAGR), from $117.24M to $79.19M.
- What does med device — gross profit mean?
- Gross profit for the medical device segment is calculated as net sales minus the direct costs associated with producing and delivering those devices. It serves as a primary indicator of the segment's ability to generate profit from its core manufacturing and sales activities before accounting for operating expenses. A healthy gross profit is essential for covering R&D and administrative costs required to sustain the business.